IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma

Julian S. Rechberger, Kendra A. Porath, Liang Zhang, Cody L. Nesvick, Randy S. Schrecengost, Jann N. Sarkaria, David J. Daniels

Open source

DOI
10.3390/pharmaceutics14050922
Published
2022-04-24
Container
Pharmaceutics
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/pharmaceutics14050922,
  title = {IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma},
  author = {Julian S. Rechberger and Kendra A. Porath and Liang Zhang and Cody L. Nesvick and Randy S. Schrecengost and Jann N. Sarkaria and David J. Daniels},
  year = {2022},
  journal = {Pharmaceutics},
  doi = {10.3390/pharmaceutics14050922},
  url = {https://doi.org/10.3390/pharmaceutics14050922}
}

RIS

TY  - JOUR
TI  - IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma
AU  - Julian S. Rechberger
AU  - Kendra A. Porath
AU  - Liang Zhang
AU  - Cody L. Nesvick
AU  - Randy S. Schrecengost
AU  - Jann N. Sarkaria
AU  - David J. Daniels
PY  - 2022
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics14050922
UR  - https://doi.org/10.3390/pharmaceutics14050922
ER  - 

APA

Rechberger, J. S., Porath, K. A., Zhang, L., Nesvick, C. L., Schrecengost, R. S., Sarkaria, J. N., & Daniels, D. J. (2022). IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14050922

Source records